Agnete B. Fredriksen
Chief Scientific Officer & Business Development · Chief Business Officer · Chief Innovation & Strategy Officer · Chief Innovation and Strategy Officer - Nykode Therapeutics ASA · Roller og eierskap på relat.no →
Kjøp0ca. 0 NOK
Salg1ca. 0 NOK
| Publisert | Selskap | Handlet via | Rolle | Type | Signal | Volum | Pris | Verdi |
|---|---|---|---|---|---|---|---|---|
| 9. juli 2025 | NYKD | Direkte | Chief Scientific Officer & Business Development | Annet Tildeling | – | 3 mill. | 0 | 0 kr |
| 1. juli 2024 | NYKD | Direkte | Chief Scientific Officer & Business Development | Annet Tildeling | – | 177,5k | 0 | 0 kr |
| 7. juli 2023 | NYKD | Direkte | Chief Business Officer | Annet Tildeling | – | 154,4k | 0 | 0 kr |
| 16. mai 2022 | NYKD | Direkte | Chief Innovation & Strategy Officer | Annet Tildeling | – | 129k | 0 | 0 kr |
| 24. september 2021 | NYKD | Direkte | Chief Innovation and Strategy Officer | Salg | – | 1,1 mill. | 0 | 0 kr |
| 7. mai 2021 | NYKD | Direkte | President and CSO | Utøvelse Opsjonsutøvelse | – | 330k | 0,65 | 214,5k kr |